ArticleBMC public health2020
Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from 2002 to 2015.
Article in BMC public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Minor tranquillizers for short-term treatment of newly onset symptoms of anxiety and distress: a systematic review with network meta-analysis of randomized trials.European archives of psychiatry and clinical neuroscience · 2024Pooled it
- Stakeholders' views on the use of psychotropic medication in older people: a systematic review.Age and ageing · 2022Pooled it
- Cost-utility analysis of benzodiazepine deprescription in primary care: a cohort study.BMC health services research · 2026Article
- Role of gender, age and rurality in benzodiazepine consumption in Catalonia, 2018-2022: a retrospective longitudinal drug utilisation study.BMJ public health · 2026Article
- Risk perception, attitudes, and quality of life in a multicomponent benzodiazepine deprescription strategy.Exploratory research in clinical and social pharmacy · 2025Article
- Self-reported sleep disturbance and inappropriate z-hypnotic use among older adults in general practice.Scandinavian journal of primary health care · 2025Article
- Diazepam Photocatalytic Degradation in Laboratory- vs. Pilot-Scale Systems: Differences in Degradation Products and Reaction Kinetics.Nanomaterials (Basel, Switzerland) · 2025Article
- Does fasting in Ramadan increase the risk of traffic accidents? A time series analysis.BMC public health · 2025Article
- Trends in Benzodiazepine and Z-Drug Prescriptions in Eastern China (2015-2021).Alpha psychiatry · 2025Article
- Benzodiazepine use in Spain: risks and perspectives on the current situation and proposals for their rational use.Frontiers in pharmacology · 2025Article
- Determinants of Benzodiazepine-Dispensing Practice Among Community Pharmacy Dispensers in Dar es Salaam, Tanzania.Advances in pharmacological and pharmaceutical sciences · 2025Article
- Use of Antidepressant and Anxiolytic Drugs in Scandinavian Countries between 2006 and 2021: A Prescription Database Study.Depression and anxiety · 2024Article
- Long-term benzodiazepine prescriptions in community psychiatry clinics.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2024Article
- Gender differences in the management of acute psychiatric episodes in the emergency department: a cross-sectional analysis of the 2017-2019 triennium.Archives of women's mental health · 2023Article
- Trends in hospital admission related to poisoning by, narcotics and psychodysleptics and poisoning by antiepileptic, sedative-hypnotic, and antiparkinsonism drugs in England and Wales between April 1999 and April 2020: An ecological study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Ten-Year Trends in Psychotropic Prescribing and Polypharmacy in Australian General Practice Patients with and without Dementia.Journal of clinical medicine · 2023Article
- Production of Bi-Compartmental Tablets by FDM 3D Printing for the Withdrawal of Diazepam.Pharmaceutics · 2023Article
- Trends and patterns of benzodiazepines and Z-drugs prescriptions in Australian general practice: A national study (2011-2018).Drug and alcohol review · 2023Article
- Utilization of psychotropic medicines in Romania during 1998-2018.Frontiers in pharmacology · 2023Article
- Global trends in antidepressant, atypical antipsychotic, and benzodiazepine use: A cross-sectional analysis of 64 countries.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients. Despite the current information on the risk-benefit balance of these drugs, their consumption remains particularly high. We determined the trend in the consumption prevalence of benzodiazepines (BZDs) and drugs related to BZDs (Z-drugs) in the population of the Health Region of Lleida to explore patterns of use and the associated characteristics associated between 2002 and 2015.
methodsAn analysis of secular trends was carried out between 2002 and 2015; the databased included all individuals from the Health Region of Lleida, which had 358,157 inhabitants in 2015, that consumed BZDs. The consumption of BZDs was evaluated using prescription billing data from the Public Health System. All types of BZDs and BZD analogues that had been approved by the drug agency were included. Trends by age and sex were investigated.
resultsOver the whole study period, a total of 161,125 individuals accounted for 338,148 dispensations. Overall, 59% were women, and the mean age was 56 years. The dispensing prevalence of BZDs use in 2015 was 14.2% overall -18.8% in women and 9.6% in men-and was 36% in those over 65 years. According to the half-life of BZDs, the prevalence of short-intermediate BZD use, intermediate-long BZD use, and Z-drugs use was 9.7, 5.5 and 0.8%, respectively. The evolution of the annual prevalence of BZD dispensing showed a progressive decline, from 15.3% in 2002 to 14.2% in 2015, which was attributed to a decrease in the consumption of intermediate-long half-life BZDs (8.0% vs. 5.5%) and Z-drugs (1.4% vs. 0.8%).
conclusionThe dispensing prevalence of BZDs and Z-drugs was high, although a small reduction was observed during this time period. The dispensing prevalence was especially high in the population over 65, despite the risk of cognitive decline and falls. Integral actions are required to lower the BZD prescription rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.